Frazier leads Series A round for Recida Therapeutics


Recida Therapeutics Inc, a biopharmaceutical company focused on developing treatments for serious antibiotic-resistant infections, has raised $8.5 million in Series A funding. Frazier Healthcare Partners led the round.

Source: Press Release

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now!